Literature DB >> 30059817

Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012.

M C van Maaren1, M Lagendijk2, M M A Tilanus-Linthorst2, L de Munck3, R M Pijnappel4, M K Schmidt5, J Wesseling6, L B Koppert2, S Siesling7.   

Abstract

BACKGROUND: The incidence of ductal carcinoma in situ (DCIS) has drastically increased over the past decades. Because DCIS is resected after diagnosis similar to invasive breast cancer, the natural cause and behaviour of DCIS is not well known. We aimed to determine breast cancer-specific survival (BCSS) and overall survival (OS) according to grade in DCIS patients after surgical treatment in the Netherlands. PATIENTS AND METHODS: All DCIS patients diagnosed between 1999 and 2012 were selected from the Netherlands Cancer Registry. The cause of death was obtained from 'Statistics Netherlands'. BCSS and OS were estimated using multivariable Cox regression in the entire cohort and stratified for grades.
RESULTS: In total, 12,256 patients were included, of whom 1509 (12.3%) presented with grade I, 3675 (30.0%) with grade II, 6064 (49.5%) with grade III and 1008 (8.2%) with an unknown grade. During a median follow-up of 7.8 years, 1138 (9.3%) deaths were observed, and 179 (1.5%) were breast cancer-related. Of these, 10 patients had grade I; 46 grade II; 95 grade III and 28 an unknown grade. After adjustment for confounding, grade II and III were related to worse BCSS than grade I with hazard ratios of 1.92 (95% confidence interval [CI]: 0.97-3.81) and 2.14 (95% CI: 1.11-4.12), respectively. No association between grades and OS was observed.
CONCLUSION: BCSS and OS in DCIS patients were excellent. Because superior rates were observed for low-grade DCIS, it seems justified to investigate whether active surveillance may be a balanced alternative for conventional surgical treatment.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer-specific survival; Breast cancer–related deaths; Ductal carcinoma in situ; Population-based study

Mesh:

Year:  2018        PMID: 30059817     DOI: 10.1016/j.ejca.2018.07.003

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study.

Authors:  Serdar Altinay; Laurent Arnould; Noella Bletard; Cecile Colpaert; Franceska Dedeurwaerdere; Benjamin Dessauvagie; Valérie Duwel; Giuseppe Floris; Stephen Fox; Clara Gerosa; Shabnam Jaffer; Eline Kurpershoek; Magali Lacroix-Triki; Andoni Laka; Kathleen Lambein; Gaëtan Marie MacGrogan; Caterina Marchió; Dolores Martin Martinez; Sharon Nofech-Mozes; Dieter Peeters; Alberto Ravarino; Emily Reisenbichler; Erika Resetkova; Souzan Sanati; Anne-Marie Schelfhout; Vera Schelfhout; Abeer M Shaaban; Renata Sinke; Claudia Maria Stanciu-Pop; Claudia Stobbe; Carolien H M van Deurzen; Koen Van de Vijver; Anne-Sophie Van Rompuy; Stephanie Verschuere; Anne Vincent-Salomon; Hannah Wen; Hélène Dano; Caroline Bouzin; Christine Galant; Mieke R Van Bockstal
Journal:  Mod Pathol       Date:  2019-09-18       Impact factor: 7.842

Review 2.  Low-risk DCIS. What is it? Observe or excise?

Authors:  Sarah E Pinder; Alastair M Thompson; Jelle Wesserling
Journal:  Virchows Arch       Date:  2021-08-27       Impact factor: 4.535

Review 3.  A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.

Authors:  Mieke R Van Bockstal; Marie C Agahozo; Linetta B Koppert; Carolien H M van Deurzen
Journal:  Int J Cancer       Date:  2019-05-08       Impact factor: 7.396

4.  Comparison of the ductal carcinoma in situ between White Americans and Chinese Americans.

Authors:  Xin-Wen Kuang; Zhi-Hong Sun; Jun-Long Song; Zhanyong Zhu; Chuang Chen
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

5.  Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands.

Authors:  Jacky D Luiten; Ernest J T Luiten; Maurice J C van der Sangen; Willem Vreuls; Lucien E M Duijm; Vivianne C G Tjan-Heijnen; Adri C Voogd
Journal:  Breast Cancer Res Treat       Date:  2021-01-01       Impact factor: 4.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.